SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Recro Pharma Q1 EPS $(0.330) Misses $(0.030) Estimate, Sales $21.777M Beat $19.450M Estimate

Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.330) per share which missed the analyst consensus estimate of $(0.030) by 1000 percent. This is a 230 percent decrease over losses of $(0.100) per share from

Benzinga · 05/11/2020 11:16

Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.330) per share which missed the analyst consensus estimate of $(0.030) by 1000 percent. This is a 230 percent decrease over losses of $(0.100) per share from the same period last year. The company reported quarterly sales of $21.777 million which beat the analyst consensus estimate of $19.450 million by 11.96 percent. This is a 13.12 percent decrease over sales of $25.065 million the same period last year.